



25 Mei 2017  
25 May 2017  
P.U. (A) 153

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)  
(NO. 2) 2017

*POISONS (AMENDMENT OF POISONS LIST) (NO. 2)  
ORDER 2017*

DISIARKAN OLEH/  
PUBLISHED BY  
JABATAN PEGUAM NEGARA/  
ATTORNEY GENERAL'S CHAMBERS

## AKTA RACUN 1952

## PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2017

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 2) 2017**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Acitretin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>          | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|-----------------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                       | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Acidinium<br>bromide | -              | All preparations”; |                |                |                |               |

- (ii) dengan memasukkan selepas butiran “Bleomycin; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Blinatumomab | -              | All preparations”; |                |                |                |               |

- (iii) dengan memasukkan selepas butiran “Bortezomib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>                                 | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--|----------------|--------------------|----------------|----------------|----------------|---------------|
|  | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Botulinum<br>toxin; natural<br>or synthetic | -              | All preparations”; |                |                |                |               |

- (iv) dengan memasukkan selepas butiran “Celecoxib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Cerebrolysin | -              | All preparations”; |                |                |                |               |

(v) dengan memasukkan selepas butiran “Dapsone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                |                    |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|----------------|--------------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i>     | <i>Group D</i> |                |               |
| “Darifenacin | -              | -              | All preparations”; |                |                |               |

(vi) dengan menggantikan butiran “Erythropoeitin” dengan butiran “Erythropoietin”;

(vii) dengan memasukkan selepas butiran “Exenatide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Ezetimibe   | -              | All preparations”; |                |                |                |               |

(viii) dengan menggantikan butiran “Fenpiramide; its salts” dengan butiran “Fenpipramide; its salts”;

- (ix) dengan memasukkan selepas butiran “Fesoteradine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Fimasartan  | -              | All preparations”; |                |                |                |               |

- (x) dalam butiran “Hydroquinone” dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

| <i>Names</i> | <i>Part I</i>  |                |  |                | <i>Part II</i>   | <i>Exempt</i>   |
|--------------|----------------|----------------|--|----------------|--|---|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i>   | <i>Group D</i> |  |   |
| Hydroquinone | “-             | -              | All medicinal preparations unless in Part II or exempted | -              | Preparations other than for medicinal purposes unless exempted | Artificial nail systems which is a notified cosmetic under the Control of Drugs and Cosmetics |

Regulations  
1984,  
containing  
hydroquinone  
not more than  
0.02% w/w”;  
notified  
cosmetic  
under the  
Control of  
Drugs and  
Cosmetics  
Regulations  
1984  
containing  
arbutin”;

(xi) dengan memasukkan selepas butiran “Idarubicin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Idarucizumab | -              | All preparations”; |                |                |                |               |

(xii) dengan menggantikan butiran “Iobitriol” dengan butiran “Iobitridol”;

(xiii) dengan memasukkan selepas butiran “Lenograstim” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Lenvatinib  | -              | All preparations”; |                |                |                |               |

(xiv) dengan memasukkan selepas butiran “Levamisole; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>   | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Levetiracetam | -              | All preparations”; |                |                |                |               |

(xv) dalam butiran “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” dengan memasukkan selepas butiran “Ropivacaine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>   |   |   |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|---|---|---|----------------|----------------|---------------|
|              | <i>Group A</i>  | <i>Group B</i>  | <i>Group C</i>  | <i>Group D</i> |                |               |
| “Tetracaine  | All condoms, appliances or preparations containing local anaesthetics unless Group B or Group C | All preparations in pharmaceutical dosage forms unless Group A or Group C | All preparations in pharmaceutical dosage form for local anaesthetics, topical use in the nose, eyes and ears, suppository or external use. |                |                |               |

Lozenges and  
pastilles unless  
Group A and  
Group B”;

(xvi) dengan memasukkan selepas butiran “Lung Phospholipid” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

| <i>Names</i>    | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|-----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                 | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Luseogliflozin | -              | All preparations”; |                |                |                |               |

(xvii) dengan memasukkan selepas butiran “Nitrophenols, ortho, meta and para” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Nivolumab   | -              | All preparations”; |                |                |                |               |

(xviii) dengan memasukkan selepas butiran “Olanzapine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Olaparib    | -              | All preparations”; |                |                |                |               |

(xix) dengan memasukkan selepas butiran “Paclitaxel” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Palbociclib | -              | All preparations”; |                |                |                |               |

- (xx) dengan memasukkan selepas butiran “Panitumumab” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Panobinostat | -              | All preparations”; |                |                |                |               |

- (xxi) dengan memasukkan selepas butiran “Pegvisomant” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>   | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pembrolizumab | -              | All preparations”; |                |                |                |               |

- (xxii) dengan menggantikan butiran “Phenethylamine” dengan butiran “Phenethylamine unless specified elsewhere in the List”;

(xxiii) dalam butiran “Phosphorus” dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

| <i>Names</i> | <i>Part I</i>  |                |                |                | <i>Part II</i>   | <i>Exempt</i>   |
|--------------|----------------|----------------|----------------|----------------|------------------|---|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i> | <i>Group D</i> |                  |   |
| Phosphorus   | -              | -              | -              | -              | All preparations | Phosphorus in food, notified cosmetic or registered product under the Control of Drugs and Cosmetics Regulations 1984”; |

(xxiv) dengan memasukkan selepas butiran “Pirenzepine; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pirfenidone | -              | All preparations”; |                |                |                |               |

(xxv) dengan memasukkan selepas butiran “Piroxicam” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>          | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|-----------------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                       | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pitavastatin calcium | -              | All preparations”; |                |                |                |               |

(xxvi) dengan memasukkan selepas butiran “Polymethylene bis trimethyl-ammonium salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pomalidomide | -              | All preparations”; |                |                |                |               |

(xxvii) dengan memasukkan selepas butiran “Sildenafil; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Silodosin   | -              | All preparations”; |                |                |                |               |

(xxviii) dengan memasukkan selepas butiran “Ulipristal” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Umeclidinium | -              | All preparations”; |                |                |                |               |

(xxix) dengan memasukkan selepas butiran “Vecuronium; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

| <i>Names</i> | <i>Part I</i>  |                        |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|------------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>         | <i>Group C</i> | <i>Group D</i> |                |               |
| “Vedolizumab | -              | All preparations”; dan |                |                |                |               |

(b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai “**Anaesthetics:**”, dengan memasukkan selepas butiran “Ropivacaine” butiran “Tetracaine”;
- (ii) dalam senarai “**Analeptics and Central Stimulants:**”, dengan memasukkan selepas butiran “Cathinone (DD)” butiran “Dexamphetamine (DD); its salts”;
- (iii) dalam senarai “**Anti-asthmatics:**”, dengan memasukkan selepas butiran “Tulobuterol” butiran “Umeclidinium”;
- (iv) dalam senarai “**Antibiotics:**”—

(A) dengan menggantikan butiran “Antibiotics, all substances of; their synthetic preparations; their salts” dengan butiran “Antibiotics, all substances of; their synthetic preparations; their salts; unless stated elsewhere in the List”; dan

- (B) dengan memasukkan selepas butiran “Avoparcin” butiran “Chloramphenicols and other substances structurally derived therefrom, their salts; their esters”;
- (v) dalam senarai “**Anticholinergics:**”—
  - (A) dengan memasukkan sebelum butiran “Atropine” butiran “Aclidinium bromide”;
  - (B) dengan memasukkan selepas butiran “Cycrimine; its salts” butiran “Darifenacin”;
  - (C) dengan memasukkan selepas butiran “Homatropine” butiran “Hyoscine”;
  - (D) dengan menggantikan butiran “Solanaceous alkaloids unless specified elsewhere in this List” dengan butiran “Solanaceous alkaloids unless specified elsewhere in the List”; dan
  - (E) dengan memasukkan selepas butiran “Tropidum; its salts” butiran “Tiotropium bromide”;
- (vi) dalam senarai “**Anticonvulsants:**”, dengan memasukkan selepas butiran “Lamotrigine” butiran “Levetiracetam”;
- (vii) dalam senarai “**Antidepressants:**”, dengan menggantikan butiran “Clofexamine; its salts” dengan butiran “Clofexamide; its salts”;
- (viii) dalam senarai “**Antidiabetics:**”—

- (A) dengan memasukkan selepas butiran “Lixisenatide” butiran “Luseogliflozin”; dan
  - (B) dengan memotong butiran “Tiotropium bromide”;
- (ix) dalam senarai “**Antihistamines:**” —
- (A) dengan menggantikan butiran “Fexofenadine, its salts”; dengan butiran “Fexofenadine”; dan
  - (B) dengan menggantikan butiran “Levocabastine”; dengan butiran “Levocabastine; its salts”;
- (x) dalam senarai “**Antihypertensives:**” —
- (A) dengan memasukkan selepas butiran “Aliskiren” butiran “Amlodipine”;
  - (B) dengan memasukkan selepas butiran “Felodipine” butiran “Fimasartan”;
  - (C) dengan memasukkan selepas butiran “Nilvadipine” butiran “Nimodipine”; dan
  - (D) dengan memasukkan selepas butiran “Olmesartan medoxomil” butiran “Oxyclonazide”;

- (xi) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
- (A) dengan memasukkan selepas butiran “Bicalutamide” butiran “Blinatumomab”;
  - (B) dengan menggantikan butiran “Emestane” dengan butiran “Exemestane”;
  - (C) dengan memasukkan selepas butiran “Lapatinib Ditosylate” butiran “Lenvatinib”;
  - (D) dengan menggantikan butiran “Leuprolide; its salts” dengan butiran “Leuprolide; its salts”;
  - (E) dengan memasukkan selepas butiran “Nilotinib” butiran “Nivolumab”;
  - (F) dengan memasukkan selepas butiran “Ofatumumab” butiran “Olaparib”;
  - (G) dengan memasukkan selepas butiran “Paclitaxel” butiran “Palbociclib”;
  - (H) dengan memasukkan selepas butiran “Panitumumab” butiran “Panobinostat”;
  - (I) dengan memasukkan selepas butiran “Pazopanib” butiran “Pembrolizumab”;

- (J) dengan memasukkan selepas butiran “Pertuzumab” butiran yang berikut:
- “Pirfenidone  
Pomalidomide”; dan
- (K) dengan memasukkan selepas butiran “Teroplerin” butiran “Thalidomide”;
- (xii) dalam senarai “**Antitussive:**”, dengan menggantikan butiran “Levodropizine; its salts” dengan butiran “Levodropropizine; its salts”;
- (xiii) dalam senarai “**Antiviral agents:**”—
- (A) dengan memasukkan selepas butiran “Acyclovir” butiran “Adefovir dipivoxil”;
- (B) dengan menggantikan butiran “Amantadine and other substances structurally derived therefrom; their salts” dengan butiran “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List”;
- (C) dengan menggantikan butiran “Nelfinavir” dengan butiran “Nelfinavir; its salts”; dan
- (D) dengan memasukkan selepas butiran “Trifluridine” butiran “Tromantadine; it salts”;

- (xiv) dalam senarai "**Hallucinogens**", dengan menggantikan butiran "2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or STP or DOM (DD)" dengan butiran "2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)";
- (xv) dalam senarai "**Hypnotics and Sedatives:**", dengan memotong butiran "Thalidomide";
- (xvi) dalam senarai "**Sympathomimetic amines**", dengan menggantikan butiran "Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both substitution and closure) or by substitution in the aromatic ring with or without substitution in the nitrogen atom unless otherwise specified elsewhere in the List or both; any salt of any substance falling within this item" dengan butiran "Adrenaline";
- (xvii) dalam senarai "**Vasodilators:**", dengan memotong butiran "Adenosine; its salts"; dan
- (xviii) dalam senarai "**Miscellaneous:**"—
- (A) dengan memotong butiran "Adefovir Dipivoxil";
- (B) dengan menggantikan butiran "Amifostin; its salts; its esters" dengan butiran "Amifostine; its salts; its esters";

- (C) dengan memasukkan selepas butiran “Boric acid and Sodium borate” butiran “Botulinum toxin; natural or synthetic”;
- (D) dengan menggantikan butiran “Cabergolide” dengan butiran “Cabergoline”;
- (E) dengan memasukkan selepas butiran “Carperidine; its salts” butiran “Cerebrolysin”;
- (F) dengan memasukkan selepas butiran “Etidronate disodium” butiran “Ezetimibe”;
- (G) dengan menggantikan butiran “Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl) methylamino]-1, 3, 7-trimethylxanthine” dengan butiran yang berikut:
  - “Gelsemium, alkaloids of  
8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine”;
- (H) dengan memasukkan selepas butiran “Ibandronic Acid” butiran “Idarucizumab”;
- (I) dengan menggantikan butiran “Mercury; its oxides; its inorganic and organic compounds unless specified elsewhere in the List” dengan butiran “Mercury”;
- (J) dengan menggantikan butiran “Nalidixic acid” dengan butiran “Nalidixic acid and other substances structurally derived therefrom; its salts”;

- (K) dengan memasukkan selepas butiran “Nicotine” butiran “Nicotinic acid”;
- (L) dengan memasukkan selepas butiran “Penicillamine; its salts” butiran “Pentosan”;
- (M) dengan menggantikan butiran “Piper methysticum” dengan butiran “Piper methysticum (kava-kava); its salts”;
- (N) dengan memasukkan selepas butiran “Pirfenoxone; its salts” butiran “Pitavastatin calcium”;
- (O) dengan memasukkan selepas butiran “Radium and other radioactive substances for therapeutic use or diagnostic use” butiran “Rafoxanide”;
- (P) dengan menggantikan butiran “Sibutramine hydrochloride” dengan butiran “Sibutramine”; dan
- (Q) dengan memasukkan selepas butiran “Sibutramine” butiran “Silodosin”.

Dibuat 4 Mei 2017  
[KKM.R.600-1/1/56; PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2017

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 2) Order 2017**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule —

(a) In the Poisons List—

- (i) by inserting after the item “Acitretin” and the particulars relating to it the following item:

| <i>Names</i>          | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|-----------------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                       | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Acidinium<br>bromide | -              | All preparations”; |                |                |                |               |

(ii) by inserting after the item “Bleomycin; its salts” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Blinatumomab | -              | All preparations”; |                |                |                |               |

(iii) by inserting after the item “Bortezomib” and the particulars relating to it the following item:

| <i>Names</i>                                 | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--|----------------|--------------------|----------------|----------------|----------------|---------------|
|  | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Botulinum<br>toxin; natural<br>or synthetic | -              | All preparations”; |                |                |                |               |

(iv) by inserting after the item “Celecoxib” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Cerebrolysin | -              | All preparations”; |                |                |                |               |

(v) by inserting after the item “Dapsone” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                |                    |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|----------------|--------------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i>     | <i>Group D</i> |                |               |
| “Darifenacin | -              | -              | All preparations”; |                |                |               |

(vi) by substituting for the item “Erythropoeitin” the item “Erythropoietin”;

(vii) by inserting after the item “Exenatide” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Ezetimibe   | -              | All preparations”; |                |                |                |               |

(viii) by substituting for the item “Fenpiramide; its salts” the item “Fenpipramide; its salts”;

(ix) by inserting after the item “Fesoteradine” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Fimasartan  | -              | All preparations”; |                |                |                |               |

(x) in the item “Hydroquinone” by substituting for the particulars relating to it the following particulars:

| <i>Names</i> | <i>Part I</i>  |                |  |                | <i>Part II</i>   | <i>Exempt</i>   |
|--------------|----------------|----------------|--|----------------|--|---|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i>   | <i>Group D</i> |  |   |
| Hydroquinone | “-             | -              | All medicinal preparations unless in Part II or exempted | -              | Preparations other than for medicinal purposes unless exempted | Artificial nail systems which is a notified cosmetic under the Control of Drugs and Cosmetics Regulations 1984, |

containing  
hydroquinone  
not more than  
0.02% w/w”;  
notified  
cosmetic  
under the  
Control of  
Drugs and  
Cosmetics  
Regulations  
1984  
containing  
arbutin”;

(xi) by inserting after the item “Idarubicin” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Idarucizumab | -              | All preparations”; |                |                |                |               |

(xii) by substituting for the item “Iobitriol” the item “Iobitridol”;

(xiii) by inserting after the item “Lenograstim” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Lenvatinib  | -              | All preparations”; |                |                |                |               |

(xiv) by inserting after the item “Levamisole; its salts” and the particulars relating to it the following item:

| <i>Names</i>   | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Levetiracetam | -              | All preparations”; |                |                |                |               |

- (xv) in the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” by inserting after the item “Ropivacaine” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>   |   |   |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|---|---|---|----------------|----------------|---------------|
|              | <i>Group A</i>  | <i>Group B</i>  | <i>Group C</i>  | <i>Group D</i> |                |               |
| “Tetracaine  | All condoms, appliances or preparations containing local anaesthetics unless Group B or Group C | All preparations in pharmaceutical dosage forms unless Group A or Group C | All preparations in pharmaceutical dosage form for local anaesthetics, topical use in the nose, eyes and ears, suppository or external use. Lozenges and pastilles unless Group A and Group B”; |                |                |               |

(xvi) by inserting after the item “Lung Phospholipid” and the particulars relating to it the following item:

| <i>Names</i>    | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|-----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                 | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Luseogliflozin | -              | All preparations”; |                |                |                |               |

(xvii) by inserting after the item “Nitrophenols, ortho, meta and para” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Nivolumab   | -              | All preparations”; |                |                |                |               |

(xviii) by inserting after the item “Olanzapine” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Olaparib    | -              | All preparations”; |                |                |                |               |

(xix) by inserting after the item “Paclitaxel” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Palbociclib | -              | All preparations’; |                |                |                |               |

(xx) by inserting after the item “Panitumumab” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Panobinostat | -              | All preparations”; |                |                |                |               |

(xxi) by inserting after the item “Pegvisomant” and the particulars relating to it the following item:

| <i>Names</i>   | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|----------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pembrolizumab | -              | All preparations”; |                |                |                |               |

(xxii) by substituting for the item “Phenethylamine” the item “Phenethylamine unless specified elsewhere in the List”;

(xxiii) in the item “Phosphorus” by substituting for the particulars relating to it the following particulars:

| <i>Names</i> | <i>Part I</i>  |                |                |                | <i>Part II</i>   | <i>Exempt</i>  |
|--------------|----------------|----------------|----------------|----------------|------------------|--|
|              | <i>Group A</i> | <i>Group B</i> | <i>Group C</i> | <i>Group D</i> |                  |  |
| Phosphorus   | “-             | -              | -              | -              | All preparations | Phosphorus in food, notified cosmetic or product under the Control of Drugs and Cosmetics Regulations 1984”; |

(xxiv) by inserting after the item “Pirenzepine; its salts” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pirfenidone | -              | All preparations”; |                |                |                |               |

(xxv) by inserting after the item “Piroxicam” and the particulars relating to it the following item:

| <i>Names</i>             | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|                          | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pitavastatin<br>calcium | -              | All preparations”; |                |                |                |               |

(xxvi) by inserting after the item “Polymethylene bis trimethyl-ammonium salts” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Pomalidomide | -              | All preparations”; |                |                |                |               |

(xxvii) by inserting after the item “Sildenafil; its salts” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                    |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|--------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>     | <i>Group C</i> | <i>Group D</i> |                |               |
| “Silodosin   | -              | All preparations”; |                |                |                |               |

(xxviii) by inserting after the item “Ulipristal” and the particulars relating to it the following item:

| <i>Names</i>  | <i>Part I</i>  |                        |                |                | <i>Part II</i> | <i>Exempt</i> |
|---------------|----------------|------------------------|----------------|----------------|----------------|---------------|
|               | <i>Group A</i> | <i>Group B</i>         | <i>Group C</i> | <i>Group D</i> |                |               |
| “Umeclidinium | -              | All preparations”; and |                |                |                |               |

(xxix) by inserting after the item “Vecuronium; its salts” and the particulars relating to it the following item:

| <i>Names</i> | <i>Part I</i>  |                        |                |                | <i>Part II</i> | <i>Exempt</i> |
|--------------|----------------|------------------------|----------------|----------------|----------------|---------------|
|              | <i>Group A</i> | <i>Group B</i>         | <i>Group C</i> | <i>Group D</i> |                |               |
| “Vedolizumab | -              | All preparations”; and |                |                |                |               |

(b) in the Appendix to the Poisons List —

(i) in the list of “**Anaesthetics:**”, by inserting after the item “Ropivacaine” the item “Tetracaine”;

(ii) in the list of “**Analeptics and Central Stimulants:**”, by inserting after the item “Cathinone (DD)” the item “Dexamphetamine (DD); its salts”;

(iii) in the list of “**Anti-asthmatics:**”, by inserting after the item “Tulobuterol” the item “Umeclidinium”;

(iv) in the list of “**Antibiotics:**” —

- (A) by substituting for the item “Antibiotics, all substances of; their synthetic preparations; their salts” the item “Antibiotics, all substances of; their synthetic preparations; their salts; unless stated elsewhere in the List”; and
- (B) by inserting after the item “Avoparcin” the item “Chloramphenicols and other substances structurally derived therefrom, their salts; their esters”;

(v) in the list of “**Anticholinergics:**” —

- (A) by inserting before the item “Atropine” the item “Aclidinium bromide”;
- (B) by inserting after the item “Cycrimine; its salts” the item “Darifenacin”;
- (C) by inserting after the item “Homatropine” the item “Hyoscine”;
- (D) by substituting for the item “Solanaceous alkaloids unless specified elsewhere in this List” the item “Solanaceous alkaloids unless specified elsewhere in the List”; and
- (E) by inserting after the item “Tropidium; its salts” the item “Tiotropium bromide”;

(vi) in the list of “**Anticonvulsants:**”, by inserting after the item “Lamotrigine” the item “Levetiracetam”;

(vii) in the list of “**Antidepressants:**”, by substituting for the item “Clofexamine; its salts” the item “Clofexamide; its salts”

(viii) in the list of “**Antidiabetics:**”—

(A) by inserting after the item “Lixisenatide” the item “Luseogliflozin”; and

(B) by deleting the item “Tiotropium bromide”;

(ix) in the list of “**Antihistamines:**”—

(A) by substituting for the item “Fexofenadine, its salts” the item “Fexofenadine”; and

(B) by substituting for the item “Levocabastine” the item “Levocabastine; its salts”;

(x) in the list of “**Antihypertensives:**”—

(A) by inserting after the item “Aliskiren” the item “Amlodipine”;

(B) by inserting after the item “Felodipine” the item “Fimasartan”;

(C) by inserting after the item “Nilvadipine” the item “Nimodipine”; and

- (D) by inserting after the item “Olmesartan medoxomil” the item “Oxyclonazide”;
- (xi) in the list of “**Antineoplastic agents and Immunosuppressants:**”—
- (A) by inserting after the item “Bicalutamide” the item “Blinatumomab”;
- (B) by substituting for the item “Emestane” the item “Exemestane”;
- (C) by inserting after the item “Lapatinib Ditosylate” the item “Lenvatinib”;
- (D) by substituting for the item “Leuprolide; its salts” the item “Leuprolide; its salts”;
- (E) by inserting after the item “Nilotinib” the item “Nivolumab”;
- (F) by inserting after the item “Ofatumumab” the item “Olaparib”;
- (G) by inserting after the item “Paclitaxel” the item “Palbociclib”;
- (H) by inserting after the item “Panitumumab” the item “Panobinostat”;
- (I) by inserting after the item “Pazopanib” the item “Pembrolizumab”;

- (J) by inserting after the item “Pertuzumab” the following items:
  - “Pirfenidone
  - Pomalidomide”; and
- (K) by inserting after the item “Teroplerin” the item “Thalidomide”;
- (xii) in the list of “**Antitussive:**”, by substituting for the item “Levodropizine; its salts” the item “Levodropropizine; its salts”;
- (xiii) in the list of “**Antiviral agents:**”—
  - (A) by inserting after the item “Acyclovir” the item “Adefovir dipivoxil”;
  - (B) by substituting for the item “Amantadine and other substances structurally derived therefrom; their salts” the item “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List”;
  - (C) by substituting for the item “Nelfinavir” the item “Nelfinavir; its salts”; and
  - (D) by inserting after the item “Trifluridine” the item “Tromantadine; it salts”;

- (xiv) in the list of "**Hallucinogens**", by substituting for the item "2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or STP or DOM (DD)" the item "2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)";
- (xv) in the list of "**Hypnotics and Sedatives:**", by deleting the item "Thalidomide";
- (xvi) in the list of "**Sympathomimetic amines**", by substituting for the item "Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both substitution and closure) or by substitution in the aromatic ring with or without substitution in the nitrogen atom unless otherwise specified elsewhere in the List or both; any salt of any substance falling within this item" the item "Adrenaline";
- (xvii) in the list of "**Vasodilators:**", by deleting the item "Adenosine; its salts"; and
- (xviii) in the list of "**Miscellaneous:**"—
- (A) by deleting the item "Adefovir Dipivoxil";
  - (B) by substituting for the item "Amifostin; its salts; its esters" the item "Amifostine; its salts; its esters";
  - (C) by inserting after the item "Boric acid and Sodium borate" the item "Botulinum toxin; natural or synthetic";
  - (D) by substituting for the item "Cabergolide" the item "Cabergoline";

- (E) by inserting after the item “Carperidine; its salts” the item “Cerebrolysin”;
- (F) by inserting after the item “Etidronate disodium” the item “Ezetimibe”;
- (G) by substituting for the item “Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl) methylamino]-1, 3, 7-trimethylxanthine” the following items:
  - “Gelsemium, alkaloids of  
8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine”;
- (H) by inserting after the item “Ibandronic Acid” the item “Idarucizumab”;
- (I) by substituting for the item “Mercury; its oxides; its inorganic and organic compounds unless specified elsewhere in the List” the item “Mercury”;
- (J) by substituting for the item “Nalidixic acid” the item “Nalidixic acid and other substances structurally derived therefrom; its salts”;
- (K) by inserting after the item “Nicotine” the item “Nicotinic acid”;
- (L) by inserting after the item “Penicillamine; its salts” the item “Pentosan”;

- (M) by substituting for the item “Piper methysticum” the item “Piper methysticum (kava-kava); its salts”;
- (N) by inserting after the item “Pirfenoxone; its salts” the item “Pitavastatin calcium”;
- (O) by inserting after the item “Radium and other radioactive substances for therapeutic use or diagnostic use” the item “Rafoxanide”;
- (P) by substituting for the item “Sibutramine hydrochloride” the item “Sibutramine”; and
- (Q) by inserting after the item “Sibutramine” the item “Silodosin”.

Made 4 May 2017  
[KKM.R.600-1/1/56; PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM  
*Minister of Health*